NEW YORK—Womble Bond Dickinson client Thorne has joined with Drs. Joel Dudley and Chris Mason to launch Pillar Health, an artificial intelligence platform designed to provide precise, actionable wellness solutions.

Womble Bond Dickinson’s Chris Gyves and Kevin Trempe handled Thorne’s corporate work for the Pillar Health project. Stephanie Yarbrough is the firm’s relationship partner for Thorne.

The Pillar Health AI platform “will leverage longitudinal sampling and in-depth measures of a person’s blood, genome, microbiome, metabolites, and environment to reveal altered or missing molecular components needed to accelerate wellness,” according to a press release. Drs. Dudley and Mason have been pioneers in this type of research, and an investment from Thorne made it possible to bring Pillar Health to the individual healthcare consumer.

Drs. Dudley and Mason say the precise, molecular-level data provided by Pillar Health will help healthcare providers provide better wellness and disease prevention solutions, individualized for each patient.

“We are laser-focused on translating impressive science into a great consumer user experience, but we also understand that companies cannot simply deliver reams of data to people, nor expect them to consistently turn over private information based on their own biomarkers without meaningful solutions,” said Thorne CEO Paul Jacobson. “Our companies, Thorne, WellnessFX and Pillar, will integrate everything and deliver it onto a single platform for actionable solutions.”

Click here to read Thorne’s press release on the launch of Pillar Health.

Chris Gyves is a seasoned corporate and securities lawyer who helps public companies overcome their most significant legal issues. He is Chair of the Firm’s Public Company Advisors Team, a multi-office team of corporate, capital markets, and tax attorneys who serve the Firm’s public-company clients. In the boardroom, Gyves counsels boards of directors on leading-edge and highly confidential transactional and governance matters and special committee investigations. He is experienced in public and private mergers and acquisitions, takeover preparedness, shareholder activism and executive compensation.

Kevin Trempe is an experienced transactions attorney who has advised clients in corporate, capital markets and economic development matters. Trempe works with domestic and international businesses in all sectors seeking to locate or expand their operations in the Southeastern United States. 

Stephanie Yarbrough has played a role in many of South Carolina’s largest economic development deals of the past 20 years. She works closely with companies seeking to expand or relocate operations to the Carolinas and the Southeastern United States. Her efforts on behalf of clients have led to the creation of thousands of new jobs and billions of dollars in new investments. When the New York Times profiled Charleston’s economic boom in 2017, Yarbrough was one of the local leaders the Times turned to for insight.

About Thorne

Thorne is a health and technology company that is disrupting prevention and wellness.  By combining dietary and lifestyle recommendations with nutritional supplement intervention, Thorne is at the forefront of personalized health, with a mission to help consumers take control of their own health and live a healthy life. Thorne provides at-home biomarker tests to bring the doctor to the consumer’s home. By leveraging its sophisticated analytical software, Thorne helps consumers uncover health insights and confidently take action to optimize healthier outcomes. Based on individual test results, Thorne’s technology and team can deliver a personalized plan on what to eat, how to exercise, and which Thorne supplements to take.

Thorne is the only supplement manufacturer to collaborate with Mayo Clinic on wellness research and content, and is the proud partner of a number of U.S. National Teams, including U.S. Soccer, USA Hockey, and USA Triathlon. Thorne is one of the fastest growing supplement companies, and is rated the top practitioner-dispensed brand among 30-40 year-olds. For more information visit